KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Income (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Net Income data on record, last reported at -$229.4 million in Q4 2025.

  • For Q4 2025, Net Income fell 118.44% year-over-year to -$229.4 million; the TTM value through Dec 2025 reached -$381.4 million, up 16.1%, while the annual FY2025 figure was -$381.4 million, 16.09% up from the prior year.
  • Net Income reached -$229.4 million in Q4 2025 per IONS's latest filing, down from -$128.6 million in the prior quarter.
  • Across five years, Net Income topped out at $325.4 million in Q4 2023 and bottomed at -$229.4 million in Q4 2025.
  • Average Net Income over 5 years is -$56.8 million, with a median of -$87.6 million recorded in 2021.
  • The widest YoY moves for Net Income: up 720.24% in 2023, down 213.69% in 2023.
  • A 5-year view of Net Income shows it stood at $254.5 million in 2021, then crashed by 120.61% to -$52.5 million in 2022, then soared by 720.24% to $325.4 million in 2023, then tumbled by 132.27% to -$105.0 million in 2024, then tumbled by 118.44% to -$229.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$229.4 million in Q4 2025, -$128.6 million in Q3 2025, and $123.6 million in Q2 2025.